Pancreatic Cancer Research

ResearcherEhime UniversityActive in the last 2 years

Yoichi Hiasa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4117-339X; OpenAlex author ID A5035134420. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 3 papers

Papers 12

  1. A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable advanced pancreatic cancer treated with firs… Last author DOI 10.1007/s10147-025-02717-1↗
  2. Clinicopathological features for clinically resectable peripherally located pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2025.06.010↗
  3. Protein kinase R regulates pancreatic ductal adenocarcinoma progression by modulating the cell cycle via GADD45A. Last author DOI 10.1038/s41598-025-06213-4↗
  4. Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome for Pancreatic Cancer Due to Early Diagn… Last author DOI 10.3390/cancers15030561↗
  5. Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.8736-21↗
  6. Apoptosis-associated speck-like protein containing a CARD regulates the growth of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-021-01465-2↗
  7. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. Last author DOI 10.1097/md.0000000000027591↗
  8. ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. Last author DOI 10.2169/internalmedicine.3748-19↗
  9. Early Detection of Pancreatic Cancer in Patients With Chronic Liver Disease Under Hepatocellular Carcinoma Surveillance. Last author DOI 10.1016/j.mayocp.2018.12.034↗
  10. Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients. Last author DOI 10.1186/s12876-017-0623-8↗
  11. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinica… Co-author DOI 10.1186/1471-230x-13-134↗
  12. Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer. First author DOI 10.1371/journal.pone.0071367↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitsuhito Koizumi · 12 shared papers, 2013–2025 · strength 1.46
  2. Teru Kumagi · 11 shared papers, 2013–2025 · strength 1.22
  3. Yoshinori Ohno · 8 shared papers, 2013–2025 · strength 0.95
  4. Taira Kuroda · 7 shared papers, 2013–2025 · strength 0.70
  5. Ichinosuke Hyodo · 4 shared papers, 2021–2025 · strength 0.67
  6. Takashi Terao · 6 shared papers, 2017–2023 · strength 0.59
  7. Akinori Asagi · 3 shared papers, 2022–2025 · strength 0.56
  8. Nobuaki Azemoto · 7 shared papers, 2013–2023 · strength 0.54
  9. Yoshinori Tanaka · 6 shared papers, 2013–2023 · strength 0.50
  10. Toru Otsuru · 2 shared papers, 2025 · strength 0.45
  11. Yuki Numata · 2 shared papers, 2025 · strength 0.42
  12. Kaori Hino · 2 shared papers, 2022–2025 · strength 0.32
  13. Hiroshi Ishii · 2 shared papers, 2019–2020 · strength 0.16
  14. Masanori Abe · 3 shared papers, 2013–2020 · strength 0.15
  15. Morikazu Onji · 2 shared papers, 2013 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.